Long COVID has debilitating effects but is inconsistently diagnosed because of subjective criteria, limited treatments, and variations in health care access. We analyzed electronic health records from ...

Shares of Arbutus Biopharma (ABUS) jumped 6% on Tuesday as investors awaited a payout from vaccine developer Moderna (MRNA) ...

Moderna's growth story is just beginning.

Find the latest covid vaccine news from Fast company. See related business and technology articles, photos, slideshows and ...

No vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events related to the vaccine reportedSOUTH SAN ...

Online content falsely claiming vaccines can be distributed through the food supply has circulated for years and a new series ...

Those who use social media or AI chatbots to find health information tend to believe misinformation about COVID-19 and MMR ...

Among healthy adults receiving the JN.1- or KP.2-adapted mRNA seasonal COVID-19 vaccine, neutralizing antibody responses were similar.

VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

A comprehensive review found that mRNA vaccines are a resoundingly safe and effective feat of modern medicine.

A massive, global review of mRNA vaccines has shown that they are very effective and safe. Reporting in The Lancet, ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.